AdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular immunotherapies less expensive and more ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could make future cellular immunotherapies less expensive and more accessible to ...

AdAlta Ltd. ( ($AU:1AD) ) just unveiled an announcement. AdAlta Limited is set to host an investor webinar to discuss its ‘East to West’ cellular ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular immunotherapies less expensive and more accessible to ...

or genetically modified T cells has been evaluated and we will review each of these cellular immunotherapy approaches in the following sections. Ex vivo activated and expanded with tumor cells Yes ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 ...

FY25 saw AdAlta (ASX:1AD) focus on increasing its corporate muscle, with two new board members and additional advisors ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...